ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024

Dale Carcione; Phoebe Spencer; Grace Pettigrew; Alan Leeb; Carla Drake-Brockman; Timothy Ford; Paul Effler

doi:10.1097/INF.0000000000004715

ACTIVE POST-MARKETING SAFETY SURVEILLANCE OF NIRSEVIMAB ADMINISTERED TO CHILDREN IN WESTERN AUSTRALIA, APRIL-JULY 2024

Pediatr Infect Dis J. 2025 Jan 3. doi: 10.1097/INF.0000000000004715. Online ahead of print.

Authors

Dale Carcione¹, Phoebe Spencer¹, Grace Pettigrew¹, Alan Leeb², Carla Drake-Brockman³, Timothy Ford^{3

4}, Paul Effler¹

Affiliations

¹ From the Communicable Disease Control Directorate, Western Australia Department of Health, Perth, Western Australia, Australia.
² Illawarra Medical Centre, Perth, Western Australia, Australia.
³ Western Australian Vaccine Safety Surveillance, Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia.
⁴ Discipline of Paediatrics, Medical School, University of Western Australia, Perth, Western Australia, Australia.

PMID: 39773919
DOI: 10.1097/INF.0000000000004715

Abstract

Children receiving nirsevimab were texted a link to an online survey to monitor adverse events following immunization. Total of 4340 parents received the link, which 1195 (27.5%) responded. Forty-seven (11.4%) of 410 children who received nirsevimab alone and 230 (29.3%) of 785 children who received nirsevimab coadministered reported any reaction. No adverse events required in-patient care or had ongoing sequelae.